Meridian Bioscience Revenue 2006-2018 | VIVO

Meridian Bioscience revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Meridian Bioscience Annual Revenue
(Millions of US $)
2018 $214
2017 $201
2016 $196
2015 $195
2014 $189
2013 $189
2012 $173
2011 $159
2010 $143
2009 $148
2008 $140
2007 $123
2006 $108
2005 $93
Meridian Bioscience Quarterly Revenue
(Millions of US $)
Q1 2018 $51
Q4 2018 $53
Q3 2018 $52
Q2 2018 $56
Q1 2017 $52
Q4 2017 $50
Q3 2017 $50
Q2 2017 $54
Q1 2016 $47
Q4 2016 $47
Q3 2016 $51
Q2 2016 $51
Q1 2015 $47
Q4 2015 $47
Q3 2015 $48
Q2 2015 $52
Q1 2014 $48
Q4 2014 $47
Q3 2014 $47
Q2 2014 $50
Q1 2013 $45
Q4 2013 $49
Q3 2013 $47
Q2 2013 $47
Q1 2012 $45
Q4 2012 $43
Q3 2012 $42
Q2 2012 $47
Q1 2011 $40
Q4 2011 $40
Q3 2011 $40
Q2 2011 $41
Q1 2010 $37
Q4 2010 $36
Q3 2010 $34
Q2 2010 $31
Q1 2009 $42
Q4 2009 $42
Q3 2009 $38
Q2 2009 $33
Q1 2008 $34
Q4 2008 $36
Q3 2008 $33
Q2 2008 $36
Q1 2007 $34
Q4 2007 $32
Q3 2007 $30
Q2 2007 $32
Q1 2006 $29
Q4 2006 $29
Q3 2006 $27
Q2 2006 $28
Q1 2005 $25
Q4 2005 $25
Q3 2005 $25
Q2 2005 $24
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.727B $0.214B
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.623B 27.80
Medtronic (MDT) Ireland $123.520B 18.06
Stryker (SYK) United States $73.875B 27.09
Boston Scientific (BSX) United States $52.874B 25.78
Baxter (BAX) United States $40.209B 25.72
Zimmer Biomet Holdings (ZBH) United States $26.486B 16.96
Smith & Nephew SNATS (SNN) United Kingdom $17.634B 0.00
Canopy Growth (CGC) Canada $15.407B 0.00
ResMed (RMD) United States $14.469B 27.44
Aurora Cannabis (ACB) Canada $9.687B 68.36
Bio-Rad Laboratories (BIO) United States $9.455B 53.94
Hill-Rom Holdings (HRC) United States $7.140B 22.08
Perrigo (PRGO) Ireland $6.601B 10.70
Insulet (PODD) United States $6.039B 2037.40
GW Pharmaceuticals (GWPH) United Kingdom $5.309B 0.00
ICU Medical (ICUI) United States $4.841B 30.14
Haemonetics (HAE) United States $4.496B 39.88
Hutchison China MediTech (HCM) China $3.961B 0.00
Agios Pharmaceuticals (AGIO) United States $3.830B 0.00
Neogen (NEOG) United States $3.332B 51.18
NuVasive (NUVA) United States $2.927B 25.53
Quidel (QDEL) United States $2.672B 24.11
Aphria (APHA) $2.518B 111.78
National Vision Holdings (EYE) United States $2.327B 45.77
HEXO (HEXO) $1.429B 0.00
Cardiovascular Systems (CSII) United States $1.402B 1006.25
Phibro Animal Health (PAHC) United States $1.308B 18.80
VAREX IMAGING (VREX) United States $1.299B 25.44
AtriCure (ATRC) United States $1.104B 0.00
Lantheus Holdings (LNTH) United States $0.968B 26.15
MacroGenics (MGNX) United States $0.967B 0.00
Cerus (CERS) United States $0.885B 0.00
PetIQ (PETQ) United States $0.872B 24.96
Omeros (OMER) United States $0.868B 0.00
NanoString Technologies (NSTG) United States $0.753B 0.00
OraSure Technologies (OSUR) United States $0.713B 31.24
Eagle Pharmaceuticals (EGRX) United States $0.705B 23.99
Evolus (EOLS) United States $0.701B 0.00
TG Therapeutics (TGTX) United States $0.650B 0.00
Surmodics (SRDX) United States $0.618B 89.94
LeMaitre Vascular (LMAT) United States $0.614B 29.21
Quanterix (QTRX) United States $0.551B 0.00
BioLife Solutions (BLFS) United States $0.397B 163.54
Vapotherm (VAPO) United States $0.371B 0.00
Rockwell Medical (RMTI) United States $0.363B 0.00
Insys Therapeutics (INSY) United States $0.358B 0.00
Utah Medical Products (UTMD) United States $0.312B 20.30
Owens & Minor (OMI) United States $0.284B 3.94
Bovie Medical (APYX) United States $0.264B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.257B 0.00
Cytosorbents (CTSO) United States $0.255B 0.00
Zynex (ZYXI) United States $0.143B 15.35
Fonar (FONR) United States $0.143B 7.64
Surface Oncology (SURF) United States $0.117B 0.00
Chimerix (CMRX) United States $0.102B 0.00
Female Health (VERU) United States $0.100B 0.00
Chembio Diagnostics (CEMI) United States $0.097B 0.00
InfuSystems Holdings (INFU) United States $0.090B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.088B 0.00
United-Guardian (UG) United States $0.087B 20.01
CAS Medical Systems (CASM) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.00
Neurotrope (NTRP) United States $0.061B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Valeritas Holdings (VLRX) United States $0.036B 0.00
Senestech (SNES) United States $0.028B 0.00
Myomo (MYO) United States $0.022B 0.00
Capricor Therapeutics (CAPR) United States $0.018B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Akers Biosciences Inc (AKER) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
NeuroMetrix (NURO) United States $0.009B 15.57